Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study in Patients After Organ Transplantation
NCT ID: NCT05162456
Last Updated: 2021-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
250 participants
OBSERVATIONAL
2021-07-01
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment
NCT04779996
COVID-19-Study of Immune Responses Following Vaccination Against SARS-CoV-2
NCT04836793
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
NCT04952766
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
NCT05164016
Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System
NCT04743388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
participants willing to receive a 3-dose vaccination schedule
participants willing to receive a 3-dose vaccination schedule
assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
participants unwilling to receive a 3rd dose of vaccination
participants who received a 2-dose vaccination schedule, unwilling to receive a 3rd dose
assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years
* Receiving two doses of the BNT162b2 vaccine
* patients post organ transplantation
Exclusion Criteria
* patients who received any other vaccine than BNT162b2
* patients considered by investigator to be unable to cooperate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Collegium Medicum w Bydgoszczy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jacek Kubica
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zbigniew Włodarczyk, Prof.
Role: STUDY_DIRECTOR
Collegium Medicum w Bydgoszczy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Transplantology and General Surgery, Dr. A. Jurasz University Hospital
Bydgoszcz, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DANTE-SIRIO 8
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.